Biology subjects

Borch, A.

Publications and source records attributed to Borch, A..

3 recordsLinked to original sources

bioRxiv2026

KIR Expression Defines a Transcriptionally Distinct CD8+ T-cell Population that Confounds Antigen-Specific T-cell Detection

HLA-C-restricted CD8+ T-cell responses remain poorly defined compared with HLA-A and HLA-B responses, despite the central role of HLA-C as both a peptide-presenting molecule and a ligand for killer-cell immunoglobulin-like receptors (KIRs). This dual function creates a major challenge for pHLA multimer-based antigen-specific T-cell analysis, as HLA-C multimers may bind CD8+ T-cells through either antigen-specific TCRs or KIRs. Here, we show that KIR expression on CD8+ T-cells drives TCR-independent binding to pHLA-C multimers, leading to overestimation of HLA-C-restricted antigen-specific T-cell responses. Using HLA-mismatched donor settings and cancer neoantigen pHLA-C multimers, we demonstrate that apparent multimer-positive CD8+ T-cells can arise from KIR-mediated recognition rather than cognate TCR specificity. We further show that KIR blockade before pHLA-C multimer staining removes non-TCR-specific binding, and applying this strategy to large-scale analysis of CMV, EBV, and SARS-CoV-2 antigens, we identify TCR-specific HLA-C-restricted CD8+ T-cell populations. Importantly, KIR-mediated pHLA-C binding is peptide-selective rather than uniform across all peptide-HLA-C complexes. Single-cell transcriptomic, phenotypic, and clonotypic analyses further demonstrate that KIR-mediated and TCR-mediated pHLA-C multimer binding define transcriptionally and clonally distinct CD8+ T-cell populations. Together, these findings establish KIR-mediated pHLA-C recognition as a major confounder in HLA-C multimer-based T-cell analysis. By separating KIR- from TCR-mediated binding, our approach provides a practical framework for accurate discovery and characterization of HLA-C-restricted antigen-specific CD8+ T-cells across viral infection and cancer.

immunology↗

bioRxiv2024

Identification and characterization of neoantigen-reactive CD8+ T cells following checkpoint blockade therapy in a pan-cancer setting

BackgroundImmune checkpoint blockade (ICB) has been approved as first-line or second-line therapies for an expanding list of malignancies. T cells recognizing mutation-derived neoantigens are hypothesized to play a major role in tumor elimination. However, the dynamics and characteristics of such neoantigen-reactive T cells (NARTs) in the context of ICB are still limitedly understood. MethodsTo explore this, tumor biopsies and peripheral blood were obtained pre- and post-treatment from 20 patients with solid metastatic tumors, in a Phase I basket trial. From whole-exome sequencing and RNA-seq data, patient-specific libraries of neopeptides were predicted and screened with DNA barcode-labeled MHC multimers for CD8+ T cell reactivity, in conjunction with the evaluation of T cell phenotype. ResultsWe were able to detect NARTs in the peripheral blood and tumor biopsies for the majority of the patients; however, we did not observe any significant difference between the disease control and progressive disease patient groups, in terms of the breadth and magnitude of the detected NARTs. We also observed that the hydrophobicity of the peptide played a role in defining neopeptides resulting in NARTs response. A trend towards a treatment-induced phenotype signature was observed in the NARTs post-treatment, with the appearance of Ki67+ CD27+ PD-1+ subsets in the PBMCs and CD39+ Ki67+ TCF-1+ subsets in the TILs. Finally, the estimation of T cells from RNAseq was increasing post versus pre-treatment for disease control patients. ConclusionOur data demonstrates the possibility of monitoring the characteristics of NARTs from tumor biopsies and peripheral blood, and that such characteristics could potentially be incorporated with other immune predictors to understand further the complexity governing clinical success for ICB therapy.

immunology↗

bioRxiv2020

The retinoic acid receptor drives neuroinflammation and fine tunes the homeostasis of interleukin-17-producing T cells

The vitamin A metabolite retinoic acid (RA) is critical for the maturation and function of the immune system, however, our knowledge regarding its role in gamma delta ({gamma}{delta}) T cells is limited. By specifically inactivating the RA receptor alpha (RAR) in type 3 lymphocytes and using a combination of fetal thymic organ cultures and single-cell RNA-sequencing we found that RA strengthened TCR signaling to limit the embryonic development of interleukin(IL)-17-producing {gamma}{delta} T cells ({gamma}{delta}T17), while at the same time it promoted their survival after birth. In adult mice, RA imposed a multi-level transcriptional program allowing {gamma}{delta}T17 cells to become activated, survive and sense interferon. Consequently, cells with inactive RAR responded poorly to immunization and produced low level of cytokines leading to near disease resistance in the experimental autoimmune encephalomyelitis model. Finally, RA was required for optimal expression of the 4{beta}1 integrin and {gamma}{delta}T17 cell infiltration to the brain. Collectively, these studies suggest that by acting at various stages during the lifetime of {gamma}{delta} T cells, RA supports their normal development, their survival and their ability to respond to inflammatory stimuli.

immunology↗